On June 2, 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing Genentech’s LUCENTIS®, will be available in the United States on July 1, 2022. BYOOVIZ™ is the first FDA approved ophthalmology biosimilar. The FDA approved BYOOVIZ™ in September 2021 for the treatment of neovascular…
